How HIV-1 Gag Manipulates Its Host Cell Proteins: A Focus on Interactors of the Nucleocapsid Domain

Overview

Journal Viruses

Publisher MDPI

Specialty Microbiology

Date 2020 Aug 23

PMID 32823718

Citations 9

Authors

Jeromine Klingler

Halina Anton

Eleonore Real

Manon Zeiger

Christiane Moog

Yves Mely

Emmanuel Boutant

Affiliations

Soon will be listed here.

Abstract

The human immunodeficiency virus (HIV-1) polyprotein Gag (Group-specific antigen) plays a central role in controlling the late phase of the viral lifecycle. Considered to be only a scaffolding protein for a long time, the structural protein Gag plays determinate and specific roles in HIV-1 replication. Indeed, via its different domains, Gag orchestrates the specific encapsidation of the genomic RNA, drives the formation of the viral particle by its auto-assembly (multimerization), binds multiple viral proteins, and interacts with a large number of cellular proteins that are needed for its functions from its translation location to the plasma membrane, where newly formed virions are released. Here, we review the interactions between HIV-1 Gag and 66 cellular proteins. Notably, we describe the techniques used to evidence these interactions, the different domains of Gag involved, and the implications of these interactions in the HIV-1 replication cycle. In the final part, we focus on the interactions involving the highly conserved nucleocapsid (NC) domain of Gag and detail the functions of the NC interactants along the viral lifecycle.

Citing Articles

MicroRNAs in HIV infection: dual regulators of viral replication and host immunity.

Mansour R, El-Sayyad G, Rizk N, Mageed S, Basiouny M, El-Sayed S Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 40029387 DOI: 10.1007/s00210-025-03893-7.

Exploring HIV-1 Maturation: A New Frontier in Antiviral Development.

McGraw A, Hillmer G, Medehincu S, Hikichi Y, Gagliardi S, Narayan K Viruses. 2024; 16(9).

PMID: 39339899 PMC: 11437483. DOI: 10.3390/v16091423.

HIV vaccination: Navigating the path to a transformative breakthrough-A review of current evidence.

Scott G, Worku D Health Sci Rep. 2024; 7(9):e70089.

PMID: 39319247 PMC: 11420300. DOI: 10.1002/hsr2.70089.

A Review of FDA-Approved Anti-HIV-1 Drugs, Anti-Gag Compounds, and Potential Strategies for HIV-1 Eradication.

Sever B, Otsuka M, Fujita M, Ciftci H Int J Mol Sci. 2024; 25(7).

PMID: 38612471 PMC: 11012182. DOI: 10.3390/ijms25073659.

The current landscape of the antimicrobial peptide melittin and its therapeutic potential.

Zhang H, Sun C, Xu N, Liu W Front Immunol. 2024; 15:1326033.

PMID: 38318188 PMC: 10838977. DOI: 10.3389/fimmu.2024.1326033.

References

Stefas E, Rucheton M, Graafland H, Moynier M, Sompeyrac C, Bahraoui E . Human plasmatic apolipoprotein H binds human immunodeficiency virus type 1 and type 2 proteins. AIDS Res Hum Retroviruses. 1997; 13(1):97-104. DOI: 10.1089/aid.1997.13.97. View

Kyei G, Dinkins C, Davis A, Roberts E, Singh S, Dong C . Autophagy pathway intersects with HIV-1 biosynthesis and regulates viral yields in macrophages. J Cell Biol. 2009; 186(2):255-68. PMC: 2717652. DOI: 10.1083/jcb.200903070. View

Bohl C, Abrahamyan L, Wood C . Human Ubc9 is involved in intracellular HIV-1 Env stability after trafficking out of the trans-Golgi network in a Gag dependent manner. PLoS One. 2013; 8(7):e69359. PMC: 3704627. DOI: 10.1371/journal.pone.0069359. View

Wiegers K, RUTTER G, Kottler H, Tessmer U, Hohenberg H, Krausslich H . Sequential steps in human immunodeficiency virus particle maturation revealed by alterations of individual Gag polyprotein cleavage sites. J Virol. 1998; 72(4):2846-54. PMC: 109729. DOI: 10.1128/JVI.72.4.2846-2854.1998. View

Kaye J, Lever A . Nonreciprocal packaging of human immunodeficiency virus type 1 and type 2 RNA: a possible role for the p2 domain of Gag in RNA encapsidation. J Virol. 1998; 72(7):5877-85. PMC: 110391. DOI: 10.1128/JVI.72.7.5877-5885.1998. View

Cen S, Guo F, Niu M, Saadatmand J, Deflassieux J, Kleiman L . The interaction between HIV-1 Gag and APOBEC3G. J Biol Chem. 2004; 279(32):33177-84. DOI: 10.1074/jbc.M402062200. View

Gottlinger H, Dorfman T, Sodroski J, Haseltine W . Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc Natl Acad Sci U S A. 1991; 88(8):3195-9. PMC: 51412. DOI: 10.1073/pnas.88.8.3195. View

Martinez N, Xue X, Berro R, Kreitzer G, Resh M . Kinesin KIF4 regulates intracellular trafficking and stability of the human immunodeficiency virus type 1 Gag polyprotein. J Virol. 2008; 82(20):9937-50. PMC: 2566262. DOI: 10.1128/JVI.00819-08. View

Na Nakorn P, Treesuwan W, Choowongkomon K, Hannongbua S, Boonyalai N . In vitro and in silico binding study of the peptide derived from HIV-1 CA-CTD and LysRS as a potential HIV-1 blocking site. J Theor Biol. 2010; 270(1):88-97. DOI: 10.1016/j.jtbi.2010.11.010. View

10.

Popov S, Popova E, Inoue M, Wu Y, Gottlinger H . HIV-1 gag recruits PACSIN2 to promote virus spreading. Proc Natl Acad Sci U S A. 2018; 115(27):7093-7098. PMC: 6142272. DOI: 10.1073/pnas.1801849115. View

11.

Gamble T, Vajdos F, Yoo S, Worthylake D, Houseweart M, Sundquist W . Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell. 1996; 87(7):1285-94. DOI: 10.1016/s0092-8674(00)81823-1. View

12.

Popova E, Popov S, Gottlinger H . Human immunodeficiency virus type 1 nucleocapsid p1 confers ESCRT pathway dependence. J Virol. 2010; 84(13):6590-7. PMC: 2903293. DOI: 10.1128/JVI.00035-10. View

13.

Sakuma R, Noser J, Ohmine S, Ikeda Y . Rhesus monkey TRIM5alpha restricts HIV-1 production through rapid degradation of viral Gag polyproteins. Nat Med. 2007; 13(5):631-5. DOI: 10.1038/nm1562. View

14.

Zhou Y, Rong L, Lu J, Pan Q, Liang C . Insulin-like growth factor II mRNA binding protein 1 associates with Gag protein of human immunodeficiency virus type 1, and its overexpression affects virus assembly. J Virol. 2008; 82(12):5683-92. PMC: 2395162. DOI: 10.1128/JVI.00189-08. View

15.

Zhai Q, Fisher R, Chung H, Myszka D, Sundquist W, Hill C . Structural and functional studies of ALIX interactions with YPX(n)L late domains of HIV-1 and EIAV. Nat Struct Mol Biol. 2007; 15(1):43-9. DOI: 10.1038/nsmb1319. View

16.

Martin-Serrano J, Yarovoy A, Perez-Caballero D, Bieniasz P, Yaravoy A . Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. Proc Natl Acad Sci U S A. 2003; 100(21):12414-9. PMC: 218772. DOI: 10.1073/pnas.2133846100. View

17.

Valiente-Echeverria F, Melnychuk L, Vyboh K, Ajamian L, Gallouzi I, Bernard N . eEF2 and Ras-GAP SH3 domain-binding protein (G3BP1) modulate stress granule assembly during HIV-1 infection. Nat Commun. 2014; 5:4819. PMC: 4978539. DOI: 10.1038/ncomms5819. View

18.

Pelchen-Matthews A, Kramer B, Marsh M . Infectious HIV-1 assembles in late endosomes in primary macrophages. J Cell Biol. 2003; 162(3):443-55. PMC: 2172706. DOI: 10.1083/jcb.200304008. View

19.

Alfadhli A, Barklis E . The roles of lipids and nucleic acids in HIV-1 assembly. Front Microbiol. 2014; 5:253. PMC: 4042026. DOI: 10.3389/fmicb.2014.00253. View

20.

Burdick R, Smith J, Chaipan C, Friew Y, Chen J, Venkatachari N . P body-associated protein Mov10 inhibits HIV-1 replication at multiple stages. J Virol. 2010; 84(19):10241-53. PMC: 2937795. DOI: 10.1128/JVI.00585-10. View